专注于制药的Royalty Pharma plc (NASDAQ:RPRX)宣布,在美国食品和药物管理局(FDA)批准一种新的精神分裂症治疗方法后,公司达成了一个重要里程碑。周四,Bristol Myers Squibb (BMS)获得FDA批准,可以将KarXT (xanomeline-trospium)以Cobenfy的商品名上市,用于治疗成年人的精神分裂症。 这项批准触发了Royalty P ...

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On Tuesday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.71 which represents no change from the prior close of $27.71. The stock opened at $27.71 and touched a low of $27 ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...